News
JMP Securities Reiterates Market Outperform on Pharvaris, Maintains $49 Price Target
14 Feb 24
News, Price Target, Reiteration, Analyst Ratings
JMP Securities Maintains Market Outperform on Pharvaris, Raises Price Target to $49
23 Jan 24
News, Price Target, Analyst Ratings
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
22 Jan 24
Biotech, News, Health Care, FDA, General
Press releases
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
6 Mar 24
News, Press Releases
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
5 Mar 24
News, Press Releases
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
22 Feb 24
News, Press Releases
Pharvaris Announces Extraordinary Meeting of Shareholders
16 Feb 24
Press Releases
Pharvaris to Present at the WSAAI Annual Meeting 2024
26 Jan 24
News, Press Releases
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22 Jan 24
Health Care, Press Releases
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
5 Jan 24
Press Releases